BPH

Urology Product Preview November 2013Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.
FDA approves label addition for PDE-5 inhibitor
FDA approves label addition for PDE-5 inhibitorThe FDA has approved a product label addition for the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) that involves its use with finasteride (Proscar).
Thulium vapoenucleation found safe, efficacious in BPHThulium vapoenucleation of the prostate provided significant and durable symptomatic improvement in benign prostatic obstruction, long-term follow-up of a clinical series showed.
Lift device for BPH earns FDA approvalThe FDA has authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.
Genetic variants linked to lower urinary tract symptoms in African-AmericansIn a study of African-American men, researchers say they’ve linked two genetic variants to severity of lower urinary tract symptoms related to BPH, giving scientists insight into the higher risk facing African-Americans.
Advances in TURP: Focus on the scienceMost urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPH
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPHA new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.
For BPH, bipolar, monopolar transurethral resection of the prostate show similar clinical efficacyIn the treatment of BPH, while both bipolar-transurethral resection of the prostate (B-TURP) and monopolar-TURP (M-TURP) have similar clinical efficacy, B-TURP is associated with fewer adverse events, according to a recent systematic review of the two modalities.
Urethral ‘lift’ offers improvements in LUTS, urinary flowA minimally invasive implant procedure led to a 50% improvement in lower urinary tract symptoms due to BPH, which was maintained for a year, results of a randomized trial showed.
Plasma vaporization found superior to TURis, TURP for BPHAs follow-up lengthens in a prospective, randomized, controlled trial, men who underwent bipolar plasma vaporization of the prostate for BPH using the “button” vapo-resection electrode continue to demonstrate significantly better symptom scores and voiding characteristics compared to their counterparts treated by bipolar transurethral resection in saline or monopolar transurethral resection of the prostate.